ANALYSIS OF THE COST EFFECTIVENESS ALLOCATED FOR VACCINATION WITH IMMUNOBIOLOGICAL DRUGS IN THE REPUBLIC OF BASHKORTOSTAN
Abstract
One of the indicators of the effectiveness of ongoing immunoprophylaxis and the use of funds is the stabilization of the incidence rate of a specific infectious disease or reduction in it, taking into account the volume of immunobiological agents (IBA) supplied.
The purpose of the study was to analyze the effectiveness of the costs allocated for vaccination with the use of IBA in the Re- public of Bashkortostan.
Material and methods. The initial materials were data from reports on the receipt of IBA under the Federal Target Program for the period of 2015-2019. In the course of the research, the method of content analysis, economic and statistical method (grouping and comparison method), ABC-123 analysis technology were used.
Results and discussion. It was revealed that an increase in the cost of purchasing and delivery of IBA leads to a decrease in the incidence of infectious diseases, except for the incidence of influenza. Against the background of a decrease in the population of the Republic of Bashkortostan by 0.6% during the period of 2017-2019, and an increase in the number of doses supplied by 65.6% dur- ing the period of 2016-2018, there is a rise in the incidence of influenza by 62,4% during the period of 2017-2019; which indicates the low effectiveness of the costs allocated for vaccination against influenza in the Republic of Bashkortostan.
About the Authors
L. M. Gabdulkhakova
ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
S. N. Ivakina
ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
L. M. Sharipova
ГБУЗ «Республиканский кожно-венерологический диспансер»
Russian Federation
Russian Federation
G. H. Akhmadullina
ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
A. R. Gabdulkhakova
ФГАОУ ВО «Казанский (Приволжский) федеральный университет»
Russian Federation
Russian Federation
References
1. Bilichenko T.N., CHuchalin A.G. Morbidity and mortality of the Russian population from acute respiratory viral infections, pneumonia and vaccination // Terapevticheskii arkhiv. 2018;90 (1): 22-26. doi: 10.17116/terarkh201890122-26 (In Russ).
2. Strategija razvitija immunoprofilaktiki infekcionnyh boleznej na period do 2035 goda: rasporjazhenie Pravitel'stva RF ot 18.09.2020 g. № 2390-r // Sobranie zakonodatel'stva RF. 2020;(40): 6298. (In Russ).
3. O perechne immunobiologicheskih lekarstvennyh preparatov, proizvodstvo kotoryh osushhestvljaetsja na vseh stadijah tehnologicheskogo processa na territorii RF, zakupka kotoryh v celjah provedenija profilakticheskih privivok, vkljuchennyh v nacional'nyj kalendar' profilakticheskih privivok, osushhestvljaetsja v 2018 i 2019 gg. Minzdravom Rossii: rasporjazhenie Pravitel'stva RF ot 23 aprelja 2018 g. № 744-r [Jelektronnyj resurs] // Garant.ru: informacionno-pravovoj portal. – M., 2014. – URL:http://base.garant.ru›71930766 (data obrashhenija: 12.04.2022). (In Russ).
4. O Programme gosudarstvennyh garantij besplatnogo okazanija grazhdanam medicinskoj pomoshhi na 2021 god i na planovyj period 2022 i 2023 godov: postanovlenie Pravitel'stva RF ot 28 dekabrja 2020 g. № 2299 // Sobranie zakonodatel'stva RF. 2021.;(2): 384. (In Russ).
5. Ivakina S.N., Zotova L.A. Zatratno-chastotnyj analiz assortimenta antigistaminnyh lekarstvennyh preparatov v aptechnyh organizacijah / Voprosy obespechenija kachestva lekarstvennyh sredstv, 2016; 2 (12):14-19. (In Russ).
Review
For citations:
Gabdulkhakova L.M., Ivakina S.N., Sharipova L.M., Akhmadullina G.H., Gabdulkhakova A.R. ANALYSIS OF THE COST EFFECTIVENESS ALLOCATED FOR VACCINATION WITH IMMUNOBIOLOGICAL DRUGS IN THE REPUBLIC OF BASHKORTOSTAN. Bashkortostan Medical Journal. 2022;17(6):77-81. (In Russ.)
Views:
76
Email this article 
